Behavioral conditioning with interferon beta-1a in humans

被引:23
|
作者
Goebel, MU
Hübell, D
Kou, W
Janssen, OE
Katsarava, Z
Limmroth, V
Schedlowski, M
机构
[1] ETH Zentrum, Swiss Fed Inst Technol, Dept Psychol & Behav Immunobiol, CH-8092 Zurich, Switzerland
[2] Univ Duisburg Essen, Fac Med, Dept Psychol Med, D-45122 Essen, Germany
[3] Univ Duisburg Essen, Dept Med, Div Endocrinol, D-45122 Essen, Germany
[4] Univ Duisburg Essen, Fac Med, Dept Neurol, D-45122 Essen, Germany
关键词
behavioral conditioning; cytokine; immune responses; interferon-beta; one-trial learning;
D O I
10.1016/j.physbeh.2005.03.021
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Behavioral conditioning is one of the most impressive demonstrations of brain-immune system interaction. Numerous animal studies have demonstrated behavioral conditioned effects on immune functions, however, human studies are rare. We investigated whether it is possible to behaviorally condition the acute response to interferon (IFN)beta-1a. In a double-blind placebo-controlled study, 30 healthy subjects received a single injection of IFN beta-1a (6MIU of REBIF (R), Serono International) (unconditioned stimulus, UCS) together with a novel drink (conditioned stimulus, CS). Blood was drawn at baseline, 4, 8, and 24 h after drug administration. Within the first 8 h peripheral granulocytes significantly increased, while monocytes, lymphocytes, T-, B- and natural killer (NK) cell numbers were significantly reduced. In parallel, body temperature, heart rate, norepinephrine and interleukin (IL)-6 plasma levels were heightened within 8 h after injection. 8 days later, all previously IFN beta-treated subjects received a subcutaneous placebo (NaCl) injection, but only 15 subjects were re-exposed to the CS (experimental group), while a control group (N=15) drank water and an additional group of subjects (n=8) remained untreated (untreated group). Blood sampling was performed at baseline and at 4, 8, and 24 h. Re-exposition to the CS did not elicit conditioned responses in the experimental group. Moreover, no differences were observed between groups. These data provide negative findings regarding behavioral conditioning of cytokine effects in humans employing a one-trial learning paradigm. (c) 2005 Published by Elsevier Inc.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
  • [21] Immunomodulatory effects of interferon beta-1a in multiple sclerosis
    Liu, ZG
    Pelfrey, CM
    Cotleur, A
    Lee, JC
    Rudick, RA
    JOURNAL OF NEUROIMMUNOLOGY, 2001, 112 (1-2) : 153 - 162
  • [22] Interferon beta-1a in primary progressive multiple sclerosis
    Leary, SM
    Thompson, AJ
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 215 - 216
  • [23] Halo Nevi Associated With Interferon Beta-1a Therapy
    Vera-Iglesias, E.
    Garcia-Arpa, M.
    Sanchez-Caminero, P.
    ACTAS DERMO-SIFILIOGRAFICAS, 2012, 103 (01): : 75 - 76
  • [24] Preclinical investigation of a new interferon beta-1a biosimilar
    Sautkina, E.
    Seregin, Y.
    Lobanova, N.
    Kukharenko, A.
    Popova, O.
    Lyashenko, A.
    Ivanov, A.
    NEW BIOTECHNOLOGY, 2012, 29 : S202 - S202
  • [25] Thyroid abnormalities related to interferon beta-1a therapy
    Abdalla, JA
    NEUROLOGY, 2002, 58 (07) : A459 - A459
  • [26] The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development
    Ucar, I.
    Ertekin, T.
    Nisari, M.
    Ceylan, D.
    Al, O.
    Ulger, H.
    FOLIA MORPHOLOGICA, 2016, 75 (02) : 257 - 263
  • [27] Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
    Alam, J
    McAllister, A
    Scaramucci, J
    Jones, W
    Rogge, M
    CLINICAL DRUG INVESTIGATION, 1997, 14 (01) : 35 - 43
  • [28] Interferon beta-1a and beta-1b for treatment of multiple sclerosis - Reply
    Durelli, L
    LANCET, 2002, 360 (9343): : 1428 - 1429
  • [29] Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis
    Minagar, Alireza
    Alexander, J. Steven
    Schwendimann, Robert N.
    Kelley, Roger E.
    Gonzalez-Toledo, Eduardo
    Jimenez, Joaquim J.
    Mauro, Lucia
    Jy, Wenche
    Smith, Stacy J.
    ARCHIVES OF NEUROLOGY, 2008, 65 (02) : 199 - 204
  • [30] A randomized controlled trial of recombinant interferon beta-1a in ALS
    Beghi, E
    Chiò, A
    Inghilleri, M
    Mazzini, L
    Micheli, A
    Mora, G
    Poloni, M
    Riva, R
    Serlenga, L
    Testa, D
    Tonali, P
    NEUROLOGY, 2000, 54 (02) : 469 - 474